Assuntos
Produtos Biológicos/provisão & distribuição , Bancos de Sangue , Doadores de Sangue/provisão & distribuição , COVID-19/epidemiologia , Necessidades e Demandas de Serviços de Saúde , Produtos Biológicos/sangue , Produtos Biológicos/isolamento & purificação , Bancos de Sangue/organização & administração , Bancos de Sangue/normas , Bancos de Sangue/estatística & dados numéricos , Bancos de Sangue/provisão & distribuição , Doadores de Sangue/estatística & dados numéricos , COVID-19/sangue , COVID-19/terapia , Necessidades e Demandas de Serviços de Saúde/organização & administração , Necessidades e Demandas de Serviços de Saúde/normas , Necessidades e Demandas de Serviços de Saúde/estatística & dados numéricos , História do Século XXI , Humanos , Imunização Passiva , Imunoglobulinas Intravenosas/sangue , Imunoglobulinas Intravenosas/isolamento & purificação , Avaliação das Necessidades , Nomogramas , Pandemias , Plasma/química , Fatores de Tempo , Estados Unidos/epidemiologia , Soroterapia para COVID-19Assuntos
Bancos de Sangue/organização & administração , Transfusão de Sangue/economia , Bancos de Sangue/economia , Transfusão de Sangue/estatística & dados numéricos , Transfusão de Sangue/tendências , Regulamentação Governamental , Humanos , Obtenção de Tecidos e Órgãos/organização & administração , Estados Unidos , United States Dept. of Health and Human ServicesRESUMO
Plasma-derived medicinal products (PDMPs) such as immunoglobulins and clotting factors are listed by the World Health Organization as essential medicines. These and other PDMPs are crucial for the prophylaxis and treatment of patients with bleeding disorders, immune deficiencies, autoimmune and inflammatory diseases, and a variety of congenital deficiency disorders. While changes in clinical practice in developed countries have reduced the need for red blood cell transfusions thereby significantly reducing the collection volumes of whole blood and recovered plasma suitable for fractionation, the need for PDMPs worldwide continues to increase. The majority of plasma supplies for the manufacture of PDMPs is met by the US commercial plasma industry. However, geographic imbalance in the collection of plasma raises concerns that local disruptions of plasma supplies could result in regional and global shortages of essential PDMPs. Plasma, which fits the definition of a strategic resource, that is, "an economically important raw material which is subject to a higher risk of supply interruption," should be considered a strategic resource comparable to energy and drinking water. Plasma collections should be increased outside the United States, including in low- and middle-income countries. The need for capacity building in these countries is an essential part to strengthen quality plasma collection. This will require changes in national and regional policies. We advocate the need for the restoration of an equitable balance of the international plasma supply to reduce the risk of supply shortages worldwide. Strategic independence of plasma should be endorsed on a global level.
Assuntos
Recursos em Saúde/provisão & distribuição , Plasma , Saúde Global/economia , Saúde Global/estatística & dados numéricos , Saúde Global/tendências , Recursos em Saúde/economia , Recursos em Saúde/estatística & dados numéricos , Humanos , Plasma/química , Plasma/imunologiaRESUMO
Blood is safer than it has ever been, however the progression of transfusion from dangerous intervention to reliable supportive care been non-linear. Disparities resulting from geography, economy, and social class persist. Some risks are known, others are unknown but predictable, and still others may be totally unpredictable. Among the known risks are infectious and immunologic events that can be calculated per unit of blood transfused. These risks vary by component. Among the unknown risks are the potential for emerging pathogens transmitted by blood and for processing or storage lesions to result in short or long-term toxicity. National registries provide some reassurance that transfusion may not affect mortality significantly beyond the first few weeks after administration. Nevertheless, transmission of novel pathogens, repeated allogeneic stimulation, and infusion of cytokines or chemokines may have unrecognized consequences. Blood safety can be effected dramatically with small investment in developing countries. In the developed world, technologies such as pathogen inactivation, antigen camouflage, component substitutes, or cell expansion promise relatively small advances in safety at substantial cost. No strategy guarantees zero-risk.
Assuntos
Doadores de Sangue , Transfusão de Sangue/normas , Qualidade de Produtos para o Consumidor , Transfusão de Sangue/métodos , Qualidade de Produtos para o Consumidor/normas , Humanos , Modelos Biológicos , Gestão da Segurança/métodos , Gestão da Segurança/organização & administração , Gestão da Segurança/normas , Reação TransfusionalRESUMO
In July 2008, a workshop sponsored by the Division of Blood Diseases and Resources of the National Heart, Lung, and Blood Institute (NHLBI) was convened to identify potential research opportunities that could advance our understanding of both the biologic and the clinical impact of the various available pathogen reduction/inactivation (PR/PI) methods of blood components (platelets [PLTs], red blood cells, and plasma) intended for allogeneic transfusion. These discussions resulted in consensus that, even though several PR/PI technologies have already been licensed and are being used in Europe and elsewhere for PLTs and plasma, concerns about possible side effects, particularly component quality and pulmonary toxicity, have impeded regulatory approval in North America (United States and Canada). Such concerns thus threaten to stall further development of these technologies. As a consequence, the NHLBI workshop participants focused on formulating a series of research-related recommendations to better understand, mitigate, and prevent these adverse effects. Other important issues identified included the need for a single method to inactivate pathogens in whole blood without damaging the various blood components; new ways to monitor the efficacy of treated components, including animal models to screen for safety; a better understanding of the effect of PR/PI-treated products on recipient alloimmunization, tolerance, and immune modulation; understanding the impact of PR/PI on various other noninfectious hazards of transfusion; and establishing methods to evaluate risk-benefit and cost-effectiveness, in particular with reference to emerging pathogens. The working group also discussed issues related to specific blood components, such as improving the process of clinical evaluation, investigating the impact of PR/PI on component storage lesions, understanding mechanisms that reduce component viability, and addressing the underlying resistance to the adoption of PR/PI-treated components. This communication summarizes the opinions of workshop participants on these issues and concludes with a list of areas for possible research that could advance the application of PR/PI methods to enhance the safety of the world's blood supplies.